Report an error

Spotted something inaccurate in “Evolocumab Clears $71K/QALY Threshold in High-Risk Patients Before First Heart Attack”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.